Buying contract manufacturing and research (CMO/CRO/EMS)
What affects buying contract manufacturing and research (cmo/cro/ems)
Biotech and drug development increases demand for buying contract manufacturing and research (cmo/cro/ems)
strengthensStrongest quotes
Bavarian Nordic · Input
“Bavarian Nordic utilizes subcontractors and CMOs as part of the supply chain”
Annual report 2025A · The company itself
Genmab · Input
“we partner with contract manufacturing organizations (CMOs) for manufacturing and production”
Annual report 2025A · The company itself
Genmab · Driver
“Genmab relies on a limited number of manufacturing organizations (CMO) and individual sites at those CMOs to produce and supply our product candidates. Genmab is also dependent on clinical research organizations to conduct key aspects of our clinical trials, and on collaboration partners to conduct some of our clinical trials.”
Annual report 2025A · The company itself
Gilead Sciences · Input
“We also depend on contract manufacturing organizations (“CMOs”) and contract testing laboratories (“CTLs”), inside and outside of the U.S., to perform manufacturing and testing activities for the majority of our API and drug products. For most of our products, including our HIV products, we use multiple CMOs so that we have both primary and back-up suppliers and manufacturing sites.”
Annual report 2025A · The company itself
Companies with exposure
Input · weakens · strength 3/3
“Bavarian Nordic utilizes subcontractors and CMOs as part of the supply chain”
Annual report 2025A · The company itself
Input · weakens · strength 3/3
“we partner with contract manufacturing organizations (CMOs) for manufacturing and production”
Annual report 2025A · The company itself
Driver · weakens · strength 3/3
“Genmab relies on a limited number of manufacturing organizations (CMO) and individual sites at those CMOs to produce and supply our product candidates. Genmab is also dependent on clinical research organizations to conduct key aspects of our clinical trials, and on collaboration partners to conduct some of our clinical trials.”
Annual report 2025A · The company itself
Input · weakens · strength 2/3
“Other clinical stage programs (68)% (33)% Total third-party costs for clinical stage programs 5% 56% Preclinical projects 13% 32% Personnel, unallocated costs and overhead 27% (3)% Total research and development expenses 1,606 1,414 1,107 14% 28% Third-party costs for epcoritamab decreased by $111 million, or 27%, in 2025 as compared to 2024, primarily due to lower CMC costs in 2025 compared to 2024 related to epcoritamab under our collaboration with AbbVie.”
Annual report 2025A · The company itself
Input · weakens · strength 2/3
“We extensively outsource our clinical trial activities and usually perform only a small portion of start-up activities in-house. We rely on third-party contract research organizations to perform most of our clinical studies, including document preparation, site identification, screening and preparation, pre-study visits, training, program management, patient enrollment, ongoing monitoring, site management and bioanalysis.”
Annual report 2025A · The company itself
Input · weakens · strength 3/3
“We also depend on contract manufacturing organizations (“CMOs”) and contract testing laboratories (“CTLs”), inside and outside of the U.S., to perform manufacturing and testing activities for the majority of our API and drug products. For most of our products, including our HIV products, we use multiple CMOs so that we have both primary and back-up suppliers and manufacturing sites.”
Annual report 2025A · The company itself
Input · weakens · strength 2/3
“The Company’s manufacturing of products requires the timely delivery of sufficient amounts of complex, high-quality components and materials. The Company’s subsidiaries operate 63 manufacturing facilities as well as sourcing from thousands of suppliers around the world.”
Annual report 2025A · The company itself
Input · weakens · strength 3/3
“The Company relies on third parties to manufacture and supply certain of our products. Any failure by or loss of a third-party manufacturer or supplier could result in delays and increased costs, which may adversely affect our business.”
Annual report 2025A · The company itself
Input · weakens · strength 3/3
“Reliance on third-party relationships and outsourcing arrangements could materially adversely affect the Company’s business. The Company depends on third parties, including suppliers, distributors, alliances with other pharmaceutical and biotechnology companies, and third-party service providers, for key aspects of its business including development, manufacture and commercialization of its products and support for its information technology (IT) systems.”
Annual report 2025A · The company itself
Input · weakens · strength 3/3
“Operational Risks We are dependent on third parties to supply data, applications and services for our products and services and are dependent on certain vendors to distribute our products.”
Annual report 2025A · The company itself
Input · weakens · strength 3/3
“We rely on third-party suppliers of data, applications and services, including data from stock exchanges and other suppliers (collectively, “Vendor Products”), and depend on the accuracy and quality of Vendor Products and the ability and willingness of such suppliers to deliver, support, enhance and develop new products on a timely and cost-effective basis.”
Annual report 2025A · The company itself
Input · weakens · strength 2/3
“In addition, certain of our most significant data and technology agreements are subject to periodic renewal or re-pricing, and we may be required to accept significantly higher fees or other less favorable commercial or legal terms in order to maintain access to key Vendor Products.”
Annual report 2025A · The company itself
Input · weakens · strength 3/3
“Certain Vendor Products are concentrated among a small number of suppliers, and we also rely on major cloud and infrastructure providers to host and deliver certain products and services, so an adverse negotiation, dispute or renewal outcome with, or our inability to replace, a key supplier or to obtain comparable data or services on acceptable terms could affect our costs or ability to deliver products and services.”
Annual report 2025A · The company itself
Input · weakens · strength 2/3
“We also rely on third-party vendors, including some competitors, to distribute our data to clients. Should any of our key vendors refuse to distribute our data for any reason or require that we pay them new or additional fees in connection with the distribution of our data, we would need to find alternative ways to distribute our data, which could increase costs or disrupt operations.”
Annual report 2025A · The company itself
Input · weakens · strength 3/3
“Research and development While the research and development strategy is designed in-house in BerGenBio, the Group leverages its network of external contract research organizations (CROs) in order to execute its development strategy. BerGenBio also collaborates with academic institutions to extend the research in areas of interest of the Group.”
Annual report 2024A · The company itself
Input · weakens · strength 3/3
“We rely on third parties for conduct of our clinical studies (Contract Research Organizations), supply of medicinal products, office supplies and housekeeping services. By end of 2024 we had 4 key suppliers.”
Annual report 2024A · The company itself
Strategy · strengthens · strength 2/3
“While the research and development strategy is designed in-house, the Company leverages our network of external contract research organizations (CROs) to execute our development strategy. BerGenBio also collaborates with academic institutions to extend research in areas of interest for the Company.”
Annual report 2024A · The company itself
Input · weakens · strength 3/3
“We do not own or operate any manufacturing facilities and depend exclusively on independent third parties for the manufacture of our products.”
Annual report 2026A · The company itself
Input · weakens · strength 3/3
“Tillverkningen av det amorfa substansmaterialet sker med bolagets patenterade tillverkningsutrustning, vilken kan förläggas hos väletablerade externa kontraktstillverkare, så kallad Contract Manufacturing Organizations (CMO). Även om produktionen sker hos externa kontraktstillverkare behåller Xspray Pharma det fulla ägandet av tillverkningsutrustningen.”
Annual report 2024A · The company itself
Input · weakens · strength 3/3
“Zealand Pharma has implemented a supply contingency plan that includes the qualification of an alternative supplier.”
Annual report 2025A · The company itself
Input · weakens · strength 2/3
“Key business relationships include academic and scientific institutions, leading contract research organizations (CROs), contract manufacturing organizations (CMOs)”
Annual report 2025A · The company itself
Input · weakens · strength 2/3
“To succeed, we collaborate broadly. Key business relationships include academic and scientific institutions, leading contract research organizations (CROs), contract manufacturing organizations (CMOs), and distribution and commercialization partners. We have commercial partnerships in place for our two leading clinical programs, petrelintide and survodutide. The north star guiding our partnership model is the maximization of patient access to our potential future innovative treatments, while ensuring organizational focus on core strategic objectives and capabilities.”
Annual report 2025A · The company itself
Input · weakens · strength 3/3
“Manufacturing of cell therapies is highly complex and ZI relies, and will continue to rely, upon third parties for process development and manufacturing of its cell therapy products, and supply of essential materials.”
Annual report 2024A · The company itself
Input · weakens · strength 2/3
“FTEs employed during the financial year 2024, and 12 FTEs per 31.12.2024 Main suppliers: Suppliers manufacturing drug products (Corden Pharma, PolyPeptide), research contract organizations (Lab- Corp), hospitals and other organizations conducting clinical studies (Nordic Society of Gynecological Oncology (NSGO), Oslo Universitetssykehus (OUS), Universitätsklinikum Halle).”
Annual report 2024A · The company itself
Strategy · strengthens · strength 2/3
“MARKNAD Växande marknader Immateriella rättigheter Preklinisk forskning Klinisk fas I Substans ges till Klinisk fas II Substans ges till patienter Klinisk fas III Registrering • • • Lämplig kandidat hittas Analys av säkerhet • • • Dubbelblindrandomiserad prövning • Ansökan om godkännande till myndigheter HÅLLBARHET Miljöarbete friska frivilliga Socialt arbete Beredningsform tas fram AKTIEN BOLAGSSTYRNING Bolagsstyrningsrapport Styrelse PARTNERSKAP cancer center, University of Pennsylvania (tasquinimod i multipelt myelom), MD Anderson Cancer Center, Texas och Stichting-Haemato-Oncologie Volwassenen Netherlands (HOVON) (tasquinimod i myelofibros) samt Stanford Medicine och Global Ophtalmic Research Center, GORC (laquinimod).”
Annual report 2024A · The company itself
Input · weakens · strength 2/3
“For example, during a market upturn, our contract manufacturers may be unable to meet our demand requirements, which may preclude us from fulfilling our customers' orders on a timely basis. The ability of these manufacturers to perform is largely outside of our control.”
Annual report 2025A · The company itself
Market · strengthens · strength 2/3
“Our Life Sciences and Diagnostics Markets segment is comprised of seven areas of activity. We provide specialty contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level.”
Annual report 2025A · The company itself
Market · strengthens · strength 2/3
“Third, our specialty contract development and manufacturing organization ("CDMO") business provides services related to and the production of synthesized oligonucleotides under pharmaceutical good manufacturing practices conditions for use as active pharmaceutical ingredients in a class of drugs that utilize nucleic acid molecules for disease therapy. BIOVECTRA capabilities include microbial fermentation, bioreagents, highly potent active pharmaceutical ingredients, peptide purification and biomanufacturing capabilities in several nucleic acid modalities. Together, our BIOVECTRA and nucleic acid solutions businesses comprise our specialty CDMO offerings to our customers providing clinical-to-commercial scale production capabilities.”
Annual report 2025A · The company itself
Strategy · strengthens · strength 2/3
“We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value.”
Annual report 2025A · The company itself
Input · weakens · strength 2/3
“Även IT-händelser eller cyberincidenter hos tredje part, som leverantörer eller kunder, kan inverka på koncernens leverans- och intjänings förmåga För att säkerställa stabila IT-miljöer och förebygga incidenter så har Berner Industrier under 2023 påbörjat en outsourcing av stöd och IT-behov. Behoven ikoncernens dotterbolag skiljer sig åt från bolag till bolag och från land till land varför en extern lösning av bassupporten funnits som en framtida lösning när kritisk massa inte finns.”
Annual report 2024A · The company itself
Strategy · strengthens · strength 2/3
“Segmentet Home Improvement verkar nästan uteslutande på den nordiska marknaden och är till övervägande del baserad på en dropship-modell med låg kapitalbindning där vi erbjuder ett brett sortiment och prismatchning.”
Annual report 2024A · The company itself
Input · weakens · strength 2/3
“Risk Factors We depend on others to manufacture some products, including pharmaceuticals, that we market and distribute.”
Annual report 2026A · The company itself
Input · weakens · strength 2/3
“We also depend on non-U.S. operations of our contract manufacturers, component suppliers and distribution partners.”
Annual report 2026A · The company itself
Input · weakens · strength 2/3
“Our relationships with our third-party alliance partners, who supply us with technology, including platforms and software, are also critical to our ability to provide many of our services and solutions that address client demands or requirements. There can be no assurance that we will be able to maintain such relationships or that such technology will be available on the expected timelines or for the anticipated prices.”
Annual report 2025A · The company itself
Input · weakens · strength 2/3
“We use third-parties, including sub-processors, to help us deliver services to our customers. These vendors, such as cloud infrastructure providers, store or process personal and confidential information for us or our customers.”
Annual report 2025A · The company itself
Input · weakens · strength 2/3
“Prisbilden för Läkemedelsutveckling Bolaget har ett entreprenöriellt förhållningssätt och verksamheten bedrivs på ett resurseffektivt sätt med en egen expertorganisation med hög kompetens inom läkemedelsutvecklingsarbete och registrering som arbetar tillsammans med opinionsledare (key opinion leaders), vetenskapliga rådgivare, strategiska partners, kontraktsforskningsorganisationer (CROs) och kontraktstillverkningsorganisationer (CMOs), bland annat för att genomföra kliniska prövningar.”
Annual report 2024A · The company itself
Driver · strengthens · strength 2/3
“Palveluiden ulkoistustrendin jatkuminen vaikuttaa positiivisesti toimialan kehitykseen.”
Annual report 2025A · The company itself
Input · weakens · strength 2/3
“Technology or service components from third parties are frequently embedded in or combined with our applications or service offerings. We are often responsible for billing the client in these arrangements and transmitting the applicable fees to the third party.”
Annual report 2025A · The company itself
Input · weakens · strength 2/3
“Further, we outsource various administration, technology, transfer agency and other services for our funds to third-party providers who may serve as a sub-agent or delegate.”
Annual report 2025A · The company itself
Input · weakens · strength 2/3
“We depend upon a small number of outside manufacturers and component suppliers, as well as other single-source suppliers, for certain products and components, and our business and operations could be disrupted if we encounter problems with these parties. For certain products we rely upon outside manufacturers to build these products or supply these components, including but not limited to certain clean energy products or components and large engines used in data center backup applications.”
Annual report 2025A · The company itself
Input · weakens · strength 2/3
“Our systems or our third-party providers' systems may fail, or we may be unable to renew or renegotiate agreements with key suppliers, which could interrupt our service, cause us to lose business, increase our costs and expose us to liability.”
Annual report 2025A · The company itself
Input · weakens · strength 2/3
“research organizations conducting clinical studies and establishing evidence for new drug candidates”
Annual report 2025A · The company itself
Input · weakens · strength 2/3
“contract manufacturers producing medicines”
Annual report 2025A · The company itself
Input · weakens · strength 2/3
“In addition, our increased use of original design manufacturers ("ODMs") to support cost efficiency and speed to market may reduce our direct control over product design, quality, sourcing and manufacturing processes, and any failure by ODM partners to meet our design specifications, quality standards, delivery requirements or compliance obligations could adversely affect our products, brand reputation, margins and results of operations.”
Annual report 2025A · The company itself
Input · weakens · strength 2/3
“Yhtiö tekee yhteistyötä tuhansien toimittajien kanssa ympäri maailman, ja toimittajia valittaessa käytetään monenlaisia kriteereitä, kuten laatua, luotettavuutta, toimitusvarmuutta, kestävää kehitystä ja hintaa.”
Annual report 2025A · The company itself
Input · weakens · strength 2/3
“We rely on third parties to provide key components of our business infrastructure. We rely on third-party service providers, both domestically and offshore, to leverage subject matter expertise and industry best practice, provide enhanced products and services, and reduce costs.”
Annual report 2025A · The company itself
Input · weakens · strength 2/3
“Although there are benefits in entering into third-party relationships with vendors and others, there are risks associated with such activities. When entering a third-party relationship, the risks associated with that activity are not passed to the third party but remain our responsibility.”
Annual report 2025A · The company itself
Input · weakens · strength 2/3
“As part of our development strategy, we often hire contract research organizations (“CROs”) to perform preclinical testing and clinical trials for drug candidates.”
Annual report 2025A · The company itself
Input · weakens · strength 2/3
“If the CROs that we hire to perform our preclinical testing and clinical trials do not meet deadlines, do not follow proper procedures, or a conflict arises between us and our CROs, our preclinical testing and clinical trials may take longer than expected, may cost more, may be delayed or may be terminated.”
Annual report 2025A · The company itself
Input · weakens · strength 2/3
“The manufacture of our products requires the timely delivery of sufficient amounts of quality components and materials from many suppliers in various countries. We work closely with our suppliers to ensure the continuity of supply, but we cannot guarantee these efforts will always be successful.”
Annual report 2025A · The company itself
Input · weakens · strength 2/3
“In some cases, we also depend on key vendors and partners to provide technology and other support for our strategic initiatives. If these vendors or partners fail to perform their obligations or otherwise cease to work with us, our ability to execute on our strategic initiatives could be adversely affected.”
Annual report 2025A · The company itself
Market · strengthens · strength 2/3
“Nolato fyller en viktig roll för att skapa värde i kundernas värdekedja när det kommer till tillverkning. Utgångspunkten från kunden är ofta att fylla ett identifierat behov från slutmarknaden, där Nolatos erbjudande kan vara en möjliggörare för att möta behoven.”
Annual report 2024A · The company itself
Input · weakens · strength 2/3
“We currently use outside suppliers for a portion of our manufacturing capacity. Outsourcing our production presents a number of risks. If our outside suppliers are unable to satisfy our demand, or experience manufacturing difficulties, delays or reduced yields, our results of operations and ability to satisfy customer demand could suffer.”
Annual report 2025A · The company itself
Input · weakens · strength 2/3
“Behovet av vidareförädling tillgodoses dels genom intern kapacitet dels genom ett nätverk av externa underleverantörer. Nätverket skapar en flexibilitet för att klara förändringar i vidareförädlingsbehov samtidigt som det även ger oss tillgång till erforderliga processer som vi inte har internt, som exempelvis lackering och svetsning.”
Annual report 2024A · The company itself
Strategy · strengthens · strength 2/3
“Yhtiö myös jatkaa 10.3.2022 julkistetun strategian mukaisesti uusien strategisten kumppaniverkostojen rakentamista saavuttaakseen skaalautuvan Go to Market - mallin, laajentaakseen omaa tarjoamaansa ja parantaakseen asiakkailleen tuottamaa arvoa yhdessä teknologia- ja implementointikumppaneiden kanssa.”
Annual report 2024A · The company itself
Strategy · strengthens · strength 2/3
“We depend upon third-party collaborators, including Sanofi and Bayer, and service providers such as CROs, outside testing laboratories, clinical investigator sites, third-party manufacturers, fill/finish providers, and product packagers and labelers, to assist us in the manufacture and preclinical and clinical development of our product candidates. We also depend, or will depend, on some of these or other third parties in connection with the commercialization of our marketed products and our product candidates and new indications for our marketed products if they are approved for marketing.”
Annual report 2025A · The company itself
Input · weakens · strength 2/3
“Production outsourced to global EMSs (Electronics Manufacturing Services)”
Annual report 2025A · The company itself
Strategy · strengthens · strength 2/3
“Production partnerships with global EMSs ... Provide asset light business model for RTX”
Annual report 2025B · From the report
Strategy · strengthens · strength 2/3
“Customer partnerships Politics and regulations Risk description A significant part of RTX’s business is based on long-term partnerships with leading international companies in the market segments where RTX operates. The cooperation with these customers is based on long-term framework agreements, and RTX’s products are an integrated part of these customers’ solutions and offerings.”
Annual report 2025A · The company itself
Input · weakens · strength 2/3
“New products and services, such as State Street Alpha and those related to wealth servicing, alternative investment management or digital assets or incorporating artificial intelligence, often also involve dependencies on third parties to, among other things, access or support innovative technologies, develop new distribution channels or form collaborative product and service offerings, and can require complex strategic alliances and joint venture relationships.”
Annual report 2025A · The company itself
Input · weakens · strength 2/3
“Genom ett nära och professionellt samarbete med leverantörer och samarbetspartners skapas förutsättning för att integrera ny teknik och innovation i möbler och produkter.”
Annual report 2024A · The company itself
Input · weakens · strength 2/3
“Bottlenecks in production continued, due in particular to high demand for lacquered products. As a result, overtime-related production costs and external sourcing costs were high, temporarily pressuring margins.”
Annual report 2025A · The company itself
Strategy · strengthens · strength 2/3
“Telesten valmistamat tuotteet valmistetaan tilauksesta, jolloin lopputuotteista ei myöskään synny romutettavaa materiaalia, kaikki tuotteet menevät asiakkaan tuotanto- tai varalaitekäyttöön.”
Annual report 2025A · The company itself
Input · weakens · strength 2/3
“We do not own or operate any manufacturing facilities and therefore depend upon independent third-party vendors for the manufacture of all products manufactured uniquely for Ulta Beauty, including Ulta Beauty Collection and Ulta Beauty branded gifts with purchase and other promotional products.”
Annual report 2026A · The company itself
Input · weakens · strength 2/3
“Our investments in external innovation include our collaboration with CRISPR, which resulted in the successful development and approval of CASGEVY; our acquisition of Semma Therapeutics, Inc.”
Annual report 2025A · The company itself
Input · weakens · strength 2/3
“(“Semma”), which established and advanced our T1D program; our expansion of our renal programs through our acquisition of Alpine Immune Sciences, Inc.”
Annual report 2025A · The company itself
Input · weakens · strength 2/3
“(“Alpine”); our mRNA therapeutic, VX-522, for treatment of CF through our collaboration with Moderna; and our intracellular therapeutic for myotonic dystrophy type 1 (“DM1”), VX-670, through our collaboration with Entrada.”
Annual report 2025A · The company itself
Input · weakens · strength 2/3
“We rely on internal capabilities and a global network of third parties to manufacture and distribute our product candidates for clinical trials, as well as our products for commercial sale and post-approval clinical trials.”
Annual report 2025A · The company itself
Input · weakens · strength 2/3
“If we or our third-party clinical trial providers, including contract research organizations (“CROs”), do not successfully conduct and manage our clinical activities or adequately comply with regulatory requirements, our clinical trials may experience delays or increased costs, and the potential regulatory approval of a product candidate or expansion of a label for a marketed product may be delayed or denied.”
Annual report 2025A · The company itself
Input · weakens · strength 2/3
“Establishing, managing and expanding our global manufacturing capabilities and supply chain, particularly as we enter new therapeutic modalities, requires significant financial commitment.”
Annual report 2025A · The company itself
Input · weakens · strength 2/3
“For example, we rely on third parties such as CROs for the day-to-day management and oversight of our clinical trials, on CMOs for active ingredient manufacturing and finishing operations, and on logistics providers for the distribution of our products.”
Annual report 2025A · The company itself
Strategy · strengthens · strength 2/3
“När det gäller inköp bygger vi vidare på den stabila grund som vår befintliga närvaro skapar. Samtidigt fortsätter vi genomföra förbättringar i värdekedjan och identifiera nya möjligheter med vår flexibla make or buy-strategi.”
Annual report 2024A · The company itself
Market · strengthens · strength 2/3
“Our products include a variety of primary proprietary packaging, containment solutions, reconstitution and transfer systems, and drug delivery systems, as well as contract manufacturing, analytical lab services and integrated solutions.”
Annual report 2025A · The company itself
Input · weakens · strength 1/3
“We also have agreements with other parties for contract production in Australia, Belgium, China, Ireland, Latvia, Mexico, the Netherlands, Spain, the United Kingdom, the United States, and Venezuela.”
Annual report unknown yearA · The company itself
Input · weakens · strength 1/3
“We utilize the services of third-party contract manufacturers around the world for certain products.”
Annual report 2025A · The company itself
Input · weakens · strength 1/3
“Ostetut tavarat ja palvelut ● Tavarat: tiedot massana tai tilavuutena tuoteryhmittäin ● Palvelut: kustannustiedot taloushallinnon tilien mukaan ● Tavarat: Ecoinvent ● Palvelut: Exiobase Ostettujen tavaroiden ja palveluiden arvoketjun alkupään päästöt (cradle-to-gate) lasketaan tuotteiden osalta toimintatietojen ja palveluiden osalta kustannustietojen perusteella.”
Annual report 2025A · The company itself